Official Opening of New Manufacturing Facility in Co. Galway

Pictured (from l-r) Minister Hildegarde Naughton TD, Jenny Melia, Executive Director and incoming CEO, Enterprise Ireland and Brian Shields, CEO Neurent Medical
 

• Event celebrated with Minister Hildegarde Naughton TD and Jenny Melia, CEO (Designate), Enterprise Ireland

• 125 new highly skilled jobs in Engineering, Quality Control, Operations, Supply Chain, and Sales and Marketing

Neurent Medical, (‘the Company’), a rapidly growing innovator in ear, nose, and throat (ENT) healthcare solutions, is delighted to announce the official opening of its new, state-of-the-art, manufacturing facility at Westlink Commercial Park in Oranmore, Co. Galway. Attended by Minister Hildegarde Naughton TD and Jenny Melia, CEO (Designate), Enterprise Ireland, the new facility marks a significant milestone for Neurent Medical and will create 125 new highly skilled jobs by the end of 2028. It will serve as the central hub for the production of the Company’s innovative NEUROMARK® system, a novel, and minimally invasive, treatment option designed to target the underlying drivers of Chronic Rhinitis.

The new facility represents a major investment in Ireland’s thriving MedTech ecosystem in Galway. The new jobs will range across key functions in Engineering, Quality Control, Operations, Supply Chain Management, and Sales and Marketing. In-house manufacturing of NEUROMARK will enable Neurent Medical to deepen its regional footprint in Galway and strengthen its control over product quality, innovation, and international distribution.

Originating from the Enterprise Ireland-supported BioInnovate Ireland Programme, Neurent Medical has grown from concept to commercialisation within a decade, emerging as one of Ireland’s MedTech success stories. Since its inception, the Company has leveraged Galway’s world-class innovation ecosystem to scale its team, secure FDA regulatory clearances, and attract top international clinical collaborators.

Hildegarde Naughton, TD, Minister of State at the Department of Children, Disability and Equality, commented: “I want to congratulate Neurent Medical on this significant achievement. Galway is known as a major player in Medical Technology, being home to 8 of the world's top 10 MedTech companies. Today’s announcement is further evidence of that and, as a native myself, I am particularly proud to see 125 new highly skilled jobs being created by a company based in Oranmore. It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market. I have no doubt, given their impressive growth to date, that this will be but one of many major achievements for the company.”

Brian Shields, CEO of Neurent Medical, added: “We’re proud to scale our operations in Galway, where the MedTech ecosystem continues to thrive. Our new Westlink facility gives us the manufacturing capacity to meet growing demand forNEUROMARK, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland. As an Irish-founded company, we’re excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world.”

Neurent Medical’s latest expansion reflects the Company’s continued progress and follows recent FDA 510(k) clearance for its next-generation NEUROMARK System, which paves the way for broader commercialisation in the United States. The Company continues to collaborate with regional enterprise partners, including Enterprise Ireland and local academic institutions, to build a strong pipeline of talent and drive the next generation of MedTech growth from the west of Ireland.

Jenny Melia, Executive Director and incoming CEO at Enterprise Ireland said, “I wish to congratulate Neurent Medical on their new state-of-the-art facility here in Galway. Today’s announcement of new jobs based here in Oranmore shows that Ireland is leading in research and development within the medical device space. Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI’s Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the NEUROMARK technology.  Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we will continue to work closely with Brian and the team at Neurent Medical to optimise their full international growth potential, creating and sustaining jobs here in the Galway region.”

Ends

About NEUROMARK® 

NEUROMARK is a novel, minimally invasive, medical device that targets overactive nerves in the nasal cavity responsible for chronic rhinitis. Approximately one in four Americans have chronic rhinitis¹, a condition that results in persistent congestion, rhinorrhea (runny nose), sneezing, and nasal itching caused by inflammation and swelling of the mucosal membrane in the nose. NEUROMARK’s unique device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery. With growing U.S. commercial momentum and strong clinical validation, the technology is poised for widespread adoption.

About Neurent Medical

Neurent Medical is pioneering innovative, non-surgical therapies for chronic inflammatory sinonasal diseases by safely targeting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, now enhanced with ENTelligent Technology™, provides ENT specialists with precision, control, and real-time feedback during treatment—helping improve patient outcomes and quality of life. In June 2025, Neurent Medical was granted FDA 510(k) clearance for its next-generation NEUROMARK® System, which paves the way for broader commercialisation in the U.S.

The company is headquartered in Galway, Ireland, with U.S. headquarters in Braintree, MA. 

For more information, visit www.neuromark.com.

Contacts:

Neurent Medical
Monica Cipollo
E: monica@neurentmedical.com

Media

FTI Consulting
Rugile Nenortaite / Paddy Berkery
M: +353 85 2779905 / +353 86 602 5988
E: neurentmedical@fticonsulting.com